September 23rd 2021, 1:30pm
Two posters presented at the European Society of Medical Oncology highlighted the unmet needs of cancer survivors.
September 19th 2021, 7:30pm
A review of current data identified areas of progress in Bruton tyrosine kinase (BTK) inhibition for patients with chronic lymphocytic leukemia (CLL).
September 15th 2021, 1:54pm
This is the third approval for zanubrutinib, which is sold as Brukinsa by BeiGene.
September 14th 2021, 6:00pm
Two posters being presented at the European Society for Medical Oncology Congress 2021 highlighted the need to provide long-term psychosocial support for adolescents who survive childhood leukemia.
September 10th 2021, 7:45pm
In a recent study, researchers were able to show how different evolutionary forces in aging blood stem cells impact whether or not someone develops acute myeloid leukemia (AML), offering insight into those at higher risk of the disease.
September 9th 2021, 11:10am
Results of a data analysis found once-daily zanubrutinib dosing in patients with mantle cell lymphoma (MCL) is safe and effective.
September 6th 2021, 2:15pm
Unlike most other cancers, the progression of hairy cell leukemia is largely driven by extended cell survival rather than increased proliferative cell fractions.
September 6th 2021, 1:00pm
Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.
September 2nd 2021, 4:25pm
The approval of zanubrutinib makes it just the second therapy indicated for this rare type of lymphoma.
September 1st 2021, 2:00pm
The findings, if confirmed in subsequent research, could prove to have significant implications, as only a small subset of patients with chronic lymphocytic leukemia (CLL) respond to chimeric antigen receptor (CAR) T-cell therapy.
